Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China

NEXT STORY
Laboratory set up in Berlin and strategic collaboration with leading German and Danish cancer coorporative groups entered to develop precision medicine for women’s cancers
PREV STORY
Genkyotex Reverse Stock Split Takes Effect
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%

author_avatar
NASDAQ Market News

RENNOVA HEALTH ANNOUNCES APPOINTMENT OF NEW CHIEF EXECUTIVE OFFICER AT JAMESTOWN MEDICAL CENTER

author_avatar
NASDAQ Market News

Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch

author_avatar
NASDAQ Market News